AstraZeneca: Syai Kh1 Continuous Glucose Monitoring System

The main articles are:

• Diabetes mellitus
• Blood glucose monitoring systems

2024: Registration by Roszdravnadzor

Roszdravnadzor has registered the Syai Kh1 continuous glucose monitoring system. AstraZeneca announced this on October 21, 2024.

The device will be launched by the Russian pharmaceutical distributor Irvin with the support of the biopharmaceutical company AstraZeneca. The Syai Kh1 is expected to go on sale in December 2024.

Thanks to to algorithms artificial intelligence Syai, Kh1 will make it possible to more accurately measure glucose levels in patients diabetes mellitus with types 1 and 2 who are on insulin therapy. Using real-time LMWG technology, Syai Kh1 will be able to transmit data to smartphone automatically and continuously every five minutes for the entire two-week sensor life. This will allow the patient to monitor glucose levels around the clock without the need for additional reading information from the sensor.

In turn, the doctor will be able to continuously monitor the patient's condition, which will eliminate undesirable events associated with a change in glucose level and, as a result, will contribute to improving the provision of medical support.

Another quality of the device is the compact size (less than a 5-ruble coin), as well as water resistance, which is especially important for children and people leading an active lifestyle.

Using the Syai Tag mobile application - a component of the LMWH system - the patient will be able to track changes in glucose level at any time, enter data on eating, exercise, drug and insulin therapy. After 14 days of using the app, a detailed report will be available to patients demonstrating how hypo- or hyperglycemia is related to activities displayed in the journal. Also in the application will be available recommendations on dietary therapy and exercise.

About 5 million patients with diabetes mellitus live in Russia in October 2024. 2 Of these, 280 thousand suffer from type 1 diabetes. Such patients must constantly measure their blood glucose levels in order to monitor the course of the disease. For patients diagnosed with type 2 diabetes mellitus, self-monitoring of blood glucose levels is an additional benefit that will allow you to safely adjust therapy and lifestyle.

Continuous glucose monitoring makes it easier for the patient and doctor to control the disease, allows you to effectively monitor the effect of certain factors on glycemia. At the same time, wearing a sensor does not prevent diabetes patients from leading their usual way of life: swimming, playing sports and traveling. Seven systems for continuous glucose monitoring have already been registered in Russia. Expanding the range of such medical devices increases accessibility to a wider range of patients, said Gagik Radikovich Galstyan, MD, Professor, Head of the Diabetic Foot Department of the National Medical Research Center of Endocrinology of the Ministry of Health of Russia, President of the Russian Diabetes Association.

Insufficient control of diabetes mellitus often causes complications of the disease. We are pleased that the third generation Syai X1 continuous glucose monitoring system will be available for Russian patients. This will make it possible to significantly improve the quality of life of people with diabetes, giving the patient the opportunity to independently control glucose levels without pain and restrictions in everyday life.  noted Anna Brashenkova, medical director of Biopharma, AstraZeneca in Russia and Eurasia.